Fundraising Fox
🦊/Companies
Sign in

Arthrosi

San Diego, US · 1 known investors

Find your way into Arthrosi

Arthrosi Therapeutics is a clinical-stage biopharmaceutical company developing treatments for gout, an inflammatory arthritis condition. Its lead molecule, AR882, is a urate-lowering agent aimed at reducing uric acid, tophi, and gout flares.

BiotechDigital HealthMedical Devices

Founders & leadership

LYLitain Yeh
Litain YehinCo-Founder & Chief Executive OfficerExecutive Officer, Director, Promoter at Arthrosi Therapeutics
SY
Shunqi YanCo-Founder & Chief Operating Officer

Investors · 1

HM Venture PartnersSan Francisco

In the news

Medpathtrial.medpath.com · Oct 2025Arthrosi snags $153M in pursuit of a new gout drug | BioPharma Divebiopharmadive.com · Oct 2025Arthrosi Secures $153 Million in Series E Financing to Complete Pivotal Development of Pozdeutinurad for the Treatment of Gout and Tophaceous Goutprnewswire.com · Oct 2025Arthrosi Secures $153M in Series E Fundingfinsmes.com · Oct 2025Arthrosi raises $153M, fueling dash toward phase 3 gout data in 2026fiercebiotech.com · Oct 2025Arthrosi Therapeutics Raises $75M in Series D Fundingfinsmes.com · Jul 2023

Frequently asked questions

What does Arthrosi do?
Arthrosi Therapeutics is a clinical-stage biopharmaceutical company developing treatments for gout, an inflammatory arthritis condition. Its lead molecule, AR882, is a urate-lowering agent aimed at reducing uric acid, tophi, and gout flares.
Who founded Arthrosi?
Arthrosi was founded by Litain Yeh, Shunqi Yan.
Who are Arthrosi's investors?
Arthrosi's investors include HM Venture Partners.
Where is Arthrosi headquartered?
Arthrosi is headquartered in San Diego, US.